Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis

References

• Enbrel® (etanercept) Prescribing Information. Thousand Oaks, CA: lmmunex Corporation, 2012
   Google Scholar
• Humira® (adalimumab) Prescribing Information. North Chicago, IL: Abbott Laboratories, 2012
   Google Scholar
• Remicade® (infliximab) Prescribing Information. Malvern, PA: Centocor Ortho Biotech, Inc., 2011
   Google Scholar
• National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis (NICE technology appraisal guidance 130). London: NIHCE, 2007
   Google Scholar
• Donahue KE, Jonas D, Hansen RA, et al. Drug therapy for rheumatoid arthritis in adults: an update. Comparative Effectiveness Review No. 55. (Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I.) AHRQ Publication No. 12-EHC025-EF. Rockville, MD: Agency for Healthcare Research and Quality, 2012. http://www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed April 23, 2013
   Google Scholar
• National Institute for Health and Clinical Excellence. Adalimumab for the treatment of adults with psoriasis (NICE technology appraisal guidance 146). London: NIHCE, 2008
   Google Scholar
• National Institute for Health and Clinical Excellence. Infliximab for the treatment of adults with psoriasis (NICE technology appraisal guidance 134). London: NIHCE, 2008
   Google Scholar
• National Institute for Health and Clinical Excellence. Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (NICE technology appraisal guidance 199). London: NIHCE, 2010
   Google Scholar
• National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for ankylosing spondylitis (NICE technology appraisal guidance 143). London: NIHCE, 2008
   Google Scholar
• Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. Manag Care Interface 2006;19:47-53
   PubMedGoogle Scholar
• Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. Manag Care Interface 2005;18:21-7
   PubMedGoogle Scholar
• Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
   PubMed Web of Science ®Google Scholar
• Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. Clin Ther 2009;31:825-35
   PubMed Web of Science ®Google Scholar
• Carter CT, Changolkar AK, Scott McKenzie R. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients. J Med Econ 2012;15:332-9
   PubMedGoogle Scholar
• Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. Am J Health Syst Pharm 2010;67:1281-7
   PubMed Web of Science ®Google Scholar
• Tang B, Rahman M, Waters HC, et al. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. Clin Ther 2008;30:1375-84
   PubMed Web of Science ®Google Scholar
• Wu E, Chen L, Birnbaum H, et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. Curr Med Res Opin 2007;23:1749-59
   PubMed Web of Science ®Google Scholar
• Weycker D, Yu EB, Woolley JM, et al. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis. Clin Ther 2005;27:646-56
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012;29:234-48
   PubMed Web of Science ®Google Scholar
• Schabert VF, Watson C, Gandra SR, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ 2012;15:264-75
   PubMedGoogle Scholar
• Zeidler J, Mittendorf T, Muller R, et al. Biologic TNF inhibiting agents for treatment of inflammatory rheumatic diseases: dosing patterns and related costs in Switzerland from a payers perspective. Health Econ Rev 2012;2:20
   PubMedGoogle Scholar
• Claxton G, Rae M, Panchal N, et al. Employer Health Benefits: 2012 Annual Survey. Menlo Park, CA: The Kaiser Family Foundation and Health Research and Educational Trust, 2012
   Google Scholar
• Centers for Medicare and Medicaid Services. Medicare 2011 national physician fee schedule relative value file. April 2011 update. Available at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Relative-Value-Files-Items/CMS1245669.html. Accessed July 9, 2013.
   Google Scholar
• STELARA® (ustekinumab) Prescribing Information. Horsham, PA: Janssen Biotech, Inc., 2012
   Google Scholar
• Moots RJ, Haraoui B, Matucci-Cerinic M, et al. Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice. Clin Exp Rheumatol 2011;29:26-34
   PubMed Web of Science ®Google Scholar
• Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. J Rheumatol 2009;36:2171-7
   PubMed Web of Science ®Google Scholar
• Schabert VF, Bruce B, Ferrufino CF, et al. Disability outcomes and dose escalation with etanercept, adalimumab, and infliximab in rheumatoid arthritis patients: a US-based retrospective comparative effectiveness study. Curr Med Res Opin 2012;28:569-80
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Gandra SR, Fox KM, et al. Tumor necrosis factor blocker dose escalation among biologic naive rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation. J Med Econ 2012;15:635-43
   PubMedGoogle Scholar
• Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. Arthritis Rheum 2005;53:872-8
   PubMed Web of Science ®Google Scholar
• Berger A, Edelsberg J, Li TT, et al. Dose intensification with infliximab in patients with rheumatoid arthritis. Ann Pharmacother 2005;39:2021-5
   PubMed Web of Science ®Google Scholar
• Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. Curr Med Res Opin 2008;24:2229-40
   PubMed Web of Science ®Google Scholar
• Ogale S, Hitraya E, Henk HJ. Patterns of biologic agent utilization among patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2011;12:204
   PubMed Web of Science ®Google Scholar
• RITUXAN® (rituximab) Prescribing Information. South San Francisco, CA: Genentech, Inc., 2012
   Google Scholar